fundraisingImmatics adds $150M ahead of anzu-cel readoutGerman biotech Immatics is raising $150 million (€128.6 million) through an underwritten offering to strengthen its balance sheet ahead of a pivotal readout for its lead cancer cell therapy, anzu- … more ➔
startupsRevier launches with €6M to develop novel cardiometabolic approachHeidelberg-based Revier Therapeutics has raised €6 million in seed financing to develop selective class IIa histone deacetylase (HDAC) inhibitors for cardiometabolic diseases. more ➔
licensingRoche licenses Hanmi obesity drug for up to $2.3BRoche’s Genentech unit has licensed global rights outside South Korea to HM17321, Hanmi Pharm’s Phase 1 obesity candidate. The deal gives Hanmi $190 million (€163 million) upfront and could be … more ➔
financeHansa takes first step toward US Nasdaq listingSweden’s Hansa Biopharma has confidentially filed paperwork with the U.S. Securities and Exchange Commission for a potential initial public offering of American depositary shares. more ➔
PixelgenSpatial biologyProximity resolution: Swedish Pixelgen raises $15.5M to take cell architecture platform globalStockholm-based Pixelgen Technologies has raised $15.5 million in an oversubscribed Series B round to expand commercialization of its Proxiome platform. The Swedish company is targeting a gap in single-cell … more ➔
ModernaRNAModerna gives mRNA oncology a shot in the armA Phase III win for Moderna and Merck’s personalized mRNA cancer vaccine has reignited investor enthusiasm for mRNA — and put BioNTech back in the spotlight. But the data are more important than … more ➔
AstraZeneca plcCancerAnother disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomigAstraZeneca has discontinued a pivotal Phase III trial of its dual checkpoint inhibitor volrustomig in metastatic non-small cell lung cancer (NSCLC), after an independent committee concluded that the … more ➔
Merck KGaAMergerMerck-Bio-Techne: One step closer to fusion, deal clears German antitrust reviewGermany’s Federal Cartel Office has cleared Merck KGaA’s planned acquisition of U.S. life sciences tools company Bio-Techne, removing one of the key regulatory hurdles to the €9.9 billion deal … more ➔
Wikipedia/Ceescamel EMAEurope withdraws Tavneos as AAV treatment and opens a gap for other complement inhibitors?The European Commission has revoked the marketing authorization for Tavneos (avacopan) in ANCA-associated vasculitis, citing unreliable efficacy data from the pivotal ADVOCATE trial and serious liver … more ➔
AgainIndustrial BiomanufacturingCopenhagen-based Again acquires US Geno to connect AI-driven discovery with industrial biomanufacturingThe Copenhagen-based biomanufacturing company is acquiring Genomatica, bringing Geno’s computational biology and industrial biotech expertise into a platform designed to move from pathway discovery … more ➔
Pixelgen
Moderna
AstraZeneca plc
Merck KGaA
Wikipedia/Ceescamel 
Again